ENOV vs IMTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Enovis Corporation presents a classic 'deep value' paradox, characterized by a stable Piotroski F-Score of 4/9 but severe bottom-line profitability issues. While the company trades at a significant discount to book value (P/B 0.93) and a very low forward P/E (6.03), its net profit margin is deeply negative at -52.69%. The stock is supported by a strong track record of earnings beats and bullish analyst targets, but this is countered by a disastrous long-term price trend and high execution risk associated with its acquisition-led growth strategy.
IMTX exhibits severe fundamental distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness in financial health and operational efficiency. While the company maintains an exceptionally strong liquidity position (Current Ratio of 11.72) and low debt, these are overshadowed by a catastrophic 64.90% year-over-year decline in revenue and deeply negative gross margins (-280.87%). The stock currently trades at a speculative premium with a Price/Sales ratio of 28.98 despite shrinking top-line growth. Any potential upside is driven by analyst price targets ($18.75) rather than current financial performance.
Compare Another Pair
Related Comparisons
ENOV vs IMTX: Head-to-Head Comparison
This page compares Enovis Corporation (ENOV) and Immatics N.V. (IMTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.